Retatrutide, a experimental dual agonist of the GLP-1 binding site and glucose-dependent insulinotropic polypeptide (GIP) binding site , is showing promising data in preliminary clinical studies. Ongoing https://shopretatrutidepeptide.com/retatrutide-research-knowledge-hub/